Top Medical Journal Demands More Trial Data From Drug Cos.

Law360, New York (November 1, 2012, 5:55 PM EDT) -- The British Medical Journal announced Monday that it would only publish studies by researchers and drugmakers that make patient-level clinical trial data available, joining GlaxoSmithKline PLC and European regulators in a recent push toward greater drug and medical device data transparency.

Beginning in January, study authors must commit to making “relevant anonymized patient-level data available on reasonable request” for their trials to be published in the journal, Editor-in-Chief Fiona Godlee wrote in an editorial.

The European Medicines Agency announced in July that it planned to require...
To view the full article, register now.